{"generic":"Dexrazoxane Hydrochloride","drugs":["Dexrazoxane Hydrochloride","Totect","Zinecard"],"mono":{"0":{"id":"jwpps0","title":"Generic Names","mono":"Dexrazoxane Hydrochloride"},"1":{"id":"jwpps1","title":"Dosing and Indications","sub":[{"id":"jwpps1b4","title":"Adult Dosing","mono":"<ul><li><b>Cardiomyopathy, Secondary to doxorubicin therapy in women with metastatic breast cancer; Prophylaxis:<\/b> dose is 10 times the doxorubicin dose (eg, dexrazoxane 500 mg\/m(2) (Zinecard(R)) for patient receiving doxorubicin 50 mg\/m(2)) administered IV within 30 minutes before doxorubicin is given<\/li><li><b>Cytotoxic antibiotic adverse reaction, Anthracycline-induced - Injection site extravasation:<\/b> initial dose (Totect(R)): 1000 mg\/m(2) body surface area over 1 to 2 hours on day 1, MAX 2000 mg; within 6 hours of extravasation; repeat the same dose 24 +\/- 3 hours on day 2, MAX 2000 mg; followed by a 500 mg\/m(2) dose after 48 +\/- 3 hours on day 3, MAX 1000 mg<\/li><\/ul>"},{"id":"jwpps1b5","title":"Pediatric Dosing","mono":"safety and effectiveness have not been established in pediatric patients (Zinecard(R) and Totect(R)) "},{"id":"jwpps1b6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, moderate to severe (CrCl less than 40 mL\/min) (Zinecard(R) and Totect(R)):<\/b> dexrazoxane should be reduced by 50% (dexrazoxane to doxorubicin ratio reduced to 5:1)<\/li><li><b>hepatic impairment (Zinecard(R)):<\/b> proportionately maintain 10:1 ratio as doxorubicin dose is decreased due to hyperbilirubinemia<\/li><\/ul>"},{"id":"jwpps1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Cardiomyopathy, Secondary to doxorubicin therapy in women with metastatic breast cancer; Prophylaxis<\/li><li>Cytotoxic antibiotic adverse reaction, Anthracycline-induced - Injection site extravasation<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Cardiotoxicity, Anthracycline-induced; Prophylaxis<br\/>"}]},"3":{"id":"jwpps3","title":"Contraindications\/Warnings","sub":[{"id":"jwpps3b9","title":"Contraindications","mono":"non-anthracycline chemotherapy regimens (Zinecard(R)) <br\/>"},{"id":"jwpps3b10","title":"Precautions","mono":"<ul><li>additive cytotoxicity (ie, leukopenia, neutropenia, and thrombocytopenia) may occur; monitoring recommended<\/li><li>cardiac toxicity, anthracycline-induced, has been reported, despite dexrazoxane therapy; monitoring recommended (Zinecard(R))<\/li><li>concomitant dimethylsulfoxide (DMSO); should not be used to treat anthracycline-induced extravasation with dexrazoxane (Totect(TM))<\/li><li>concomitant chemotherapy initiation with fluorouracil, doxorubicin (if cumulative dose is below 300 mg\/m(2)), and cyclophosphamide not recommended (Zinecard(R))<\/li><li>pregnancy; may cause fetal harm<\/li><li>renal impairment (CrCl less than 40 mL\/min); dose adjustment recommended<\/li><li>secondary malignancies (ie, acute myeloid leukemia, myelodysplastic syndrome) have been reported with concurrent chemotherapy in pediatric patients (unapproved use) and in adults (Zinecard(R))<\/li><\/ul>"},{"id":"jwpps3b11","title":"Pregnancy Category","mono":"Dexrazoxane: D (FDA)<br\/>"},{"id":"jwpps3b12","title":"Breast Feeding","mono":"Dexrazoxane: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jwpps4","title":"Drug Interactions","sub":{"1":{"id":"jwpps4b14","title":"Major","mono":"<ul><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><\/ul>"}}},"5":{"id":"jwpps5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site pain (12% to 16%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (43% (extravasation)), Vomiting (19% (extravasation))<\/li><li><b>Hematologic:<\/b>Decreased hemoglobin (43% (extravasation)), Leukopenia (73% (extravasation)), Neutropenia (61% (extravasation)), Thrombocytopenia (26% (extravasation))<\/li><li><b>Hepatic:<\/b>ALT\/SGPT level raised (22% (extravasation)), AST\/SGOT level raised (28% (extravasation))<\/li><li><b>Other:<\/b>Fever (21% (extravasation)), Postoperative infection (16% (extravasation))<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Myelosuppression, Secondary malignant neoplastic disease<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><\/ul>"},"6":{"id":"jwpps6","title":"Drug Name Info","sub":{"0":{"id":"jwpps6b17","title":"US Trade Names","mono":"<ul><li>Zinecard<\/li><li>Totect<\/li><\/ul>"},"2":{"id":"jwpps6b19","title":"Class","mono":"<ul><li>Cardioprotective Agent<\/li><li>Dermatological Agent<\/li><\/ul>"},"3":{"id":"jwpps6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jwpps6b21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"jwpps7","title":"Mechanism Of Action","mono":"<ul><li>Totect(TM): The mechanism is unknown. It has been proposed that dexrazoxane inhibits topoisomerase II reversibly, thereby diminishing tissue damage from extravasation of anthracycline.<\/li><li>Zinecard(R): The mechanism of action of dexrazoxane hydrochloride's cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of ethylenediamine tetra-acetic acid (EDTA) that readily penetrates cell membranes. Laboratory studies suggest that dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. Dexrazoxane does not affect the pharmacokinetics of doxorubicin .<\/li><\/ul>"},"8":{"id":"jwpps8","title":"Pharmacokinetics","sub":{"1":{"id":"jwpps8b24","title":"Distribution","mono":"<ul><li>Vd: 25 L\/m(2) <\/li><li>Protein binding: none<\/li><\/ul>"},"3":{"id":"jwpps8b26","title":"Excretion","mono":"<ul><li>Renal: 42% <\/li><li>Fecal: minimal<\/li><\/ul>"},"4":{"id":"jwpps8b27","title":"Elimination Half Life","mono":"Adults: 2 to 3 hr .<br\/>"}}},"9":{"id":"jwpps9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>use procedures for proper handling and disposal of anticancer drugs<\/li><li>wash exposed skin or mucosa immediately with soap and water if contact occurs<\/li><\/ul><\/li><li><b>Intravenous<\/b><br\/><ul><li>reconstitute Zinecard(R) with sterile water for injection to give a concentration of 10 mg\/mL<\/li><li>reconstituted Zinecard(R) solution must be further diluted with LR to a concentration of 1.3 to 3 mg\/mL<\/li><li>administer Zinecard(R) by rapid drip IV infusion<\/li><li>do NOT administer Zinecard(R) by IV push<\/li><li>do not give doxorubicin prior to dexrazoxane (Zinecard(R))<\/li><li>doxorubicin should be administered after the dexrazoxane (Zinecard(R)) infusion is complete but within 30 minutes after the beginning of the dexrazoxane infusion<\/li><li>reconstituted Zinecard(R) solution is stable for 30 minutes at room temperature or for up to 3 hours under refrigeration (2 to 8 degrees C or 36 to 46 degrees F)<\/li><li>diluted (Zinecard(R)) infusion solution is stable for 1 hour at room temperature or for up to 4 hours under refrigeration (2 to 8 degrees C or 36 to 46 degrees F)<\/li><li>reconstitute Totect(R) with 50 mL of diluent provided to yield a 10 mg\/mL solution; mixed solution is stable for up to 2 hours<\/li><li>further dilute the Totect(R) solution in an infusion bag with 1000 mL NS; the final solution is slightly yellow and is stable for 4 hours when kept below 25 degrees C (77 degrees F)<\/li><li>administer Totect(R) over 1 to 2 hours in a large caliber vein in an extremity or area other than the one affected by the extravasating<\/li><li>cooling procedures, such as ice packs, may be used but should be removed at least 15 minutes before Totect(R) administration in order to allow sufficient blood flow to the area of extravasation<\/li><\/ul><\/li><\/ul>"},"10":{"id":"jwpps10","title":"Monitoring","mono":"<ul><li>cardiac function<\/li><li> CBC<\/li><li>liver function test<\/li><\/ul>"},"11":{"id":"jwpps11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Intravenous Powder for Solution: 250 MG, 500 MG<br\/><\/li><li><b>Totect<\/b><br\/>Intravenous Powder for Solution: 500 MG<br\/><\/li><li><b>Zinecard<\/b><br\/>Intravenous Powder for Solution: 250 MG, 500 MG<br\/><\/li><\/ul>"},"12":{"id":"jwpps12","title":"Toxicology","sub":[{"id":"jwpps12b31","title":"Clinical Effects","mono":"<b>DEXRAZOXANE<\/b><br\/>OVERDOSE: Limited human data. ADVERSE EFFECTS:  Leukopenia, granulocytopenia, thrombocytopenia, anemia, and elevated serum amylase, transaminase and bilirubin levels. Prolonged PT\/ PTT and decreased fibrinogen levels have been reported in children. Increased urinary excretion of calcium, iron, and zinc.<br\/>"},{"id":"jwpps12b32","title":"Treatment","mono":"<b>DEXRAZOXANE<\/b><br\/><ul><li>Decontamination: Not indicated.<\/li><li>Myelosuppression: Protective isolation, transfusion, treat possible infections.<\/li><li>Monitoring of patient: CBC, serum calcium, liver enzymes, and fluid regulation.<\/li><\/ul>"},{"id":"jwpps12b33","title":"Range of Toxicity","mono":"<b>DEXRAZOXANE<\/b><br\/>OVERDOSE: No data available regarding overdose. Myelosuppression common with doses greater than 1000 mg\/m(2). <br\/>"}]},"13":{"id":"jwpps13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea, vomiting, diarrhea, and stomatitis.<\/li><li>Instruct patient to report signs\/symptoms of myelosuppression (leukopenia, neutropenia, thrombocytopenia) or infection.<\/li><li>Inform patient that the doses of Totect(TM) on days 2 and 3 should be started at about the same time of day (within 3 hours) as the first dose.<\/li><\/ul>"}}}